Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared Kelly Shanahan’s on X:
“Real world data suggest that chemo (cape, eribulin, taxanes) outperforms a second topo1 ADC after progression on T-DXd. Key question to address in breast oncology (and across oncology fields!). “
Quoting Kelly Shanahan’s, Director at Metavivor Research and Support, post on X:
“What about ADC sequencing?”
Insightful article about Breast Cancer.
